Echocardiographic monitoring for clozapine cardiac toxicity: Lessons from real-world experience

Australasian Psychiatry

Volumn 21, Issue 3, 2013, Pages 258-261

  Murch, Stuart ^a   Tran, Nga ^a   Liew, Danny ^a   Petrakis, Melissa ^a,b   Prior, David ^a   Castle, David ^a  

^a ST VINCENT S HOSPITAL   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Cardiomyopathy; Clozapine; Echocardiography; Myocarditis

Indexed keywords

CLOZAPINE;

ADULT; AGED; AORTA STENOSIS; ARTICLE; CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL ARTICLE; COHORT ANALYSIS; CORONARY ARTERY DISEASE; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEALTH CARE COST; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HUMAN; LONGITUDINAL STUDY; MALE; MYOCARDITIS; PREVALENCE; RETROSPECTIVE STUDY;

CARDIOMYOPATHY; CLOZAPINE; ECHOCARDIOGRAPHY; MYOCARDITIS;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; CARDIOMYOPATHIES; CLOZAPINE; COHORT STUDIES; ECHOCARDIOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; VENTRICULAR FUNCTION, LEFT;

EID: 84880723218     PISSN: 10398562     EISSN: 14401665     Source Type: Journal    
DOI: 10.1177/1039856213475684     Document Type: Article

References (17)

1. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789-796.
2. Alvir JM, Lieberman JA, Safferman AZ, et al. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 1993; 329: 162-167.
3. Buckley NA and Sanders P. Cardiovascular adverse effects of antipsychotic drugs. Drug Saf 2000; 23: 215-228.
4. Haas SJ, Hill R, Krum H, et al. Clozapine-associated myocarditis: A review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003. Drug Saf 2007; 30: 47-57.
5. Kilian JG, Kerr K, Lawrence C, et al. Myocarditis and cardiomyopathy associated with clozapine. Lancet 1999; 354: 1841-1845.
6. Hägg S, Spigset O, Bate A, et al. Myocarditis related to clozapine treatment. J Clin Psychopharmacol 2001; 21: 382-388.
7. La Grenade L, Graham D and Trontell A. Myocarditis and cardiomyopathy associated with clozapine use in the United States. N Engl J Med 2001; 345: 224-225.
8. Merrill DB, Ahmari SE, Bradford J-ME, et al. Myocarditis during clozapine treatment. Am J Psychiatry 2006; 163: 204-208.
9. Degner D, Bleich S, Grohmann R, et al. Myocarditis associated with clozapine treatment. Aust N Z J Psychiatry 2000; 34: 880.
10. Annamraju S, Sheitman B, Saik S, et al. Early recognition of clozapine-induced myocarditis. J Clin Psychopharmacol 2007; 27: 479-483.
11. Ariyarajah V, Shaikh N, Garber PJ, et al. Cardiovascular magnetic resonance in mild to moderate clozapine-induced myocarditis: Is there a role in the absence of electrocardiographic and echocardiographic abnormalities? J Magn Reson Imaging 2010; 31: 1473-1476.
12. Ronaldson KJ, Fitzgerald PB, Taylor AJ, et al. A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls. Aust N Z J Psychiatry 2011; 45: 458-465.
13. Layland JJ, Liew D and Prior DL. Clozapine-induced cardiotoxicity: A clinical update. Med J Aust 2009; 190: 190-192.
14. Bresee LC, Majumdar SR, Patten SB, et al. Prevalence of cardiovascular risk factors and disease in people with schizophrenia: A population-based study. Schizophr Res 2010; 117: 75-82.
15. Kelly DL, Wehring HJ, Linthicum J, et al. Cardiac-related findings at autopsy in people with severe mental illness treated with clozapine or risperidone. Schizophr Res 2009; 107: 134-138.
16. Berk M, Fitzsimons J, Lambert T, et al. Monitoring the safe use of clozapine: A consensus view from Victoria, Australia. CNS Drugs 2007; 21: 117-127.
17. Australian Government. Medicare Benefits Schedule Book. Australian Government Department of Health and Ageing, 2012.